|Articles|February 10, 2023
SCOPE 2023: Biospecimen Presentation Questions & Insights
Author(s)Lisa Henderson
Hope Meely, chief clinical officer at Slope, discusses the feedback she received following her SCOPE presentation around biospecimen collection.
Advertisement
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Hope Meely, chief clinical officer at Slope, elaborates on the feedback she received surrounding her conference presentation, "The Hidden Regulatory Risk from Sample Management — What Should You Be Aware of?” This includes the agreement among attendees that the clinical trials industry needs to ensure that biospecimens are managed, especially since they are the driving factors of safety and efficacy data.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What Needs to Be True Across Sponsors, Sites, and Regulators for Operation TrialBlazer to Succeed
2
ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP Treatment
3
Curavit Acquires Lindus Health Clinical Research Organization Assets to Expand US and European Trial Operations
4
When the Slack Runs Out: AI and the CRO Operating Model
5